New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology.
Xingyu ZhouDong XuMeng Tao LiXiao-Feng ZengPublished in: Expert opinion on investigational drugs (2024)
Unlinked pathobiology with symptoms resulted in misidentified targets and disappointing trials. Useful stratification tools are necessary for the heterogeneous SS patients. Composite endpoints or improvements in ESSDAI scores are needed, considering the high placebo response, and the unbalance between symptom burden and disease activity. Compared to classic biologics, targeted cell therapy will be a more promising field of investigation in the coming years.
Keyphrases
- cell therapy
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- end stage renal disease
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- chronic kidney disease
- ankylosing spondylitis
- stem cells
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- cancer therapy
- patient reported
- risk factors
- case report
- double blind
- drug induced